Nontuberculous Mycobacterial Pulmonary Disease: Patients, Principles, and Prospects

Clin Infect Dis. 2024 Oct 15;79(4):e27-e47. doi: 10.1093/cid/ciae421.

Abstract

Nontuberculous mycobacterial pulmonary disease (NTM-PD) is increasing in incidence globally and challenging to manage. The 2020 multisociety treatment guideline and the 2022 consensus recommendations provide comprehensive evidence-based guides to manage pulmonary diseases caused by the most common NTM. However, with >190 different NTM species that may require different multidrug regimens for treatment, the breadth and complexity of NTM-PD remain daunting for both patients and clinicians. In this narrative review, we aim to distill this broad, complex field into principles applicable to most NTM species and highlight important nuances, specifically elaborating on the presentation, diagnosis, principles of patient-centered care, principles of pathogen-directed therapy, and prospects of NTM-PD.

Keywords: bronchiectasis; cystic fibrosis; mycobacteria; mycobacterium; mycobacteroides.

Publication types

  • Review

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Humans
  • Lung Diseases / diagnosis
  • Lung Diseases / drug therapy
  • Lung Diseases / microbiology
  • Mycobacterium Infections, Nontuberculous* / diagnosis
  • Mycobacterium Infections, Nontuberculous* / drug therapy
  • Mycobacterium Infections, Nontuberculous* / epidemiology
  • Mycobacterium Infections, Nontuberculous* / microbiology
  • Nontuberculous Mycobacteria*

Substances

  • Anti-Bacterial Agents